Last reviewed · How we verify
NCT04515706
Iguratimod in Systemic Sclerosis
NA trial testing Iguratimod in Systemic Sclerosis, Diffuse in 20 participants. Status unknown.
31 January 2023
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 January 2021 |
| Primary completion | 31 January 2023 |
| Estimated completion | 31 January 2024 |
Drugs / interventions tested
- Iguratimod (IGURATIMOD) — full drug profile →
- Placebo
Conditions studied
- Systemic Sclerosis, Diffuse — all drugs for Systemic Sclerosis, Diffuse →
Sponsor
RenJi Hospital
Who can join
Adults 19 to 74, any sex, with Systemic Sclerosis, Diffuse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety, tolerability and efficacy of iguratimod in adult subjects with diffuse cutaneous systemic sclerosis.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Future Treatment Options in Systemic Sclerosis-Potential Targets and Ongoing Clinical Trials.
Bohdziewicz A, Pawlik KK, Maciejewska M, Sikora M, et al · · 2022 · cited 21× · PMID 35268401 · DOI 10.3390/jcm11051310 -
Macrophage migration inhibitory factor (MIF) in CNS diseases: Functional regulation and potential therapeutic indication.
Zhang Y, Yu Z, Ye N, Zhen X. · · 2024 · cited 7× · PMID 39734533 · DOI 10.1016/j.fmre.2023.05.008
Verify or expand the search:
- PubMed search for NCT04515706
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Iguratimod
Trials testing the same drug.
- NCT07057778 — Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP · Phase 2 · not yet recruiting
- NCT06244628 — Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD · Phase 3 · unknown
- NCT05302024 — Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia · Phase 2 · unknown
- NCT05626348 — The Clinical Efficacy of Immunomodulators in RA Patients · Phase 4 · recruiting
- NCT05281068 — The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia · Phase 2 · unknown
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04515706 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 17 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04515706.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing